Clinical Endpoints News Today

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial...

INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody...

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY® injection Presentation highlights include data for...

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY® (fremanezumab) injectionPresentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when...

Carlsbad, CA (PRWEB) May 05, 2022 -- NAD3® is a multi-patents-pending nutraceutical containing a unique Wasabi Japonica extract, Theacrine and

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to...

Share this article Share this article ResearchAndMarkets.coms offering. Designing for Recruitment and Retention in Rare Disease Studies report takes a deep dive into two areas impacting the success of these studies: recruitment and retention. Given the importance of each rare disease patient, these activities are time-intensive and resource-heavy. We asked 125 respondents involved in these activities about the challenges they face, methods and support services used, and their perspectives and ...